Practitioner's Docket No. 701586-54555

PATENT

IN THE UNITED STATES RECEIVING OFFICE

PCT/US2004/033178	08.10.2004 08 October 2004	09.10.2003 09 October 2003	
International	International	International Earliest	
Application Number	Filing Date	Priority Date	

TITLE OF INVENTION: METHODS AND COMPOSITIONS USING ADIPONECTIN FOR TREATMENT OF CARDIAC DISORDERS AND FOR STIMULATION OF ANGIOCENESIS

APPLICANT(S) FOR EO/DO: The Trustees of Boston University INVENTOR(S)/APPLICANT(S) FOR US: Kenneth WALSH et al.

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV653003045US in an engergipe appliesped by MAIL STOP Commissioner for Patents, P. Ö. Box 1450-A46-author 1, 2231-31450.

Date: April 6.2006

Lings M. Ginsberg

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References B1 and C1-C5 cited in the attached Forms PTO/SB/08 a and b.

REMARKS

filed:	In ac	cordance with the provisions of 37 C.F.R. §1.97, this statement is being
_ <u>x</u> _	(1)	within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits; or
	(2)	within three months of the mailing date of the PCT International Search Report; or

International Application Number: PCT/US2004/033178 International Filing Date: 08 October 2004 International Earliest Priority Date: 09 October 2003 Page 2 of 2

	(3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$180.00, is included herein; or
_	(4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.
<u>x</u>	A copy of the International Search Report is enclosed herewith.
	It is respectfully requested that each of the documents shown on the attached
	form(s) PTO/SB/08a and b be made of record in this application.
	Copies of these documents (CHECK ONE):
X	are enclosed herewith; or
	have been cited in the parent application, and are thus not being resubmitted

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Respectfully submitted, Date: April 6, 2006

> Ronald I. Eisenstein (Reg. No. 30,628) J. Amelia Feulner (Reg. No. 58,039) NIXON PEABODY LLP

100 Summer Street Boston, MA 02110-2131 (617) 345-6054

10-/5-7-4-8-2-8 1632

					TABLE BOOK A DIFFERENCE A C. ADD OR
Substitute	stitute for form 1449A/PTO			Complete of KNOWN OO APR 20	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned		
			LA. Filing Date	October 8, 2004	
		First Named Inventor	Kenneth Walsh		
		Art Unit	To be assigned		
				Examiner Name	To be assigned
Sheet	1	of	2	Attorney Docket Number	701586-54555

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
		Number - Kind Code ² (if known)			Passages or Relevant Figures Appear
	-	US-			
	1	US-			
		US-			
	1	US-			
		US-			

		FC	DREIGN PATENT D	OCUMENTS			
Examiner Initials	Cite No 1	Foreign Patent Document Kind Code ² Country Code ³ Number ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Pater Applicant of Cited	Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
/M.W./	Bl	WO 2004/105786	12-09-2004	Pharmagene Lab LTD et al.	ooratories		
Examiner Signature		/Michael Wilson/ (09/08/20	008)	Date Considered	09	9/08/2008	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

non-consumers. include copy or this tour was not wants communities on one of payments.

Applicant's implication designate citation designates (capitally 2-8c Kinds Codes of USPTO Palent) Documents at 222 uspto gov or MPEP 901 04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese passes documents, the indication of the year of the reign of the Emperor must preced the serial number of the patent document. ³ Not of documents by the appropriate symbols as indicated on the document under WIPO Standard ST.31 (if ir possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

10/4574828 632

Substitute for form 1449A/PTO To be assigned Application Number INFORMATION DISCLOSURE October 8, 2004 I.A. Filing Date STATEMENT BY APPLICANT Kenneth Walsh First Named Inventor (use as many sheets as necessary) To be assigned Art Unit To be assigned **Examiner Name** Sheet of 2 Attorney Docket Number 701586-54555 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, eatalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publishers. Cite No. T2 CI DIEZ, Juan J. et al.; European Journal of Endocrinology; 148:293-300 (2003) /M.W./ KUBOTA, Naoto et al.; The Journal of Biological Chemistry; 277(29):25863-25866 /M.W./ (July 19, 2002) MATSUDA, Morihiro et al.; The Journal of Biological Chemistry; 277(40):37487-37491 C3 (October 4, 2002) /M.W./ OUCHI, Noriyuki et al.; The Journal of Biological Chemistry; 279(2):1304-1309 C4 (January 9, 2004) /M.W SHIBATA, Rei et al.; The Journal of Biological Chemistry; 279(27):28670-28674 (July 2, /M.W. 2004)

Examiner Signature	/Michael Wilson/ (09/08/2008)	Date Considered	09/08/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.